Publications by authors named "Pierre Demolis"

Claim this Profile
H
How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers.
Silvia Stacchiotti, Pan Pantziarka, Hugh Leonard, Caroline Voltz, Laura Abatedaga, Pierre Demolis

Cancer Treat Rev· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A model structure for describing uncertainties in benefit-risk assessment of oncology drug applications.
Nikolaos Zafiropoulos, Francesco Pignatti, Andreas Kouroumalis, Lorenzo Guizzaro, Dominik Karres, Pierre Demolis

Front Med (Lausanne)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expedited Approval in Oncology: A Study of European Regulators' Perspectives and Trade-Offs.
Francesco Pignatti, Filip Josephson, Pierre Demolis, Olli Tenhunen, Elias Péan

Clin Pharmacol Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration.
Andrew Dj Pearson, Susan Chi, Theodore W Laetscht, Lynley Marshall, Elizabeth Raetz, Pierre Demolis

Eur J Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel PET RANO BM 1.0 criteria: Regulatory perspectives on new endpoint definitions in brain metastases.
Francesco Pignatti, Ralf Herold, Pierre Demolis, Ulrich-Peter Rohr

Neuro Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop.
Madeline Pe, Caroline Voltz-Girolt, Jill Bell, Vishal Bhatnagar, Jan Bogaerts, Pierre Demolis

Lancet Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating the complexity: reflections on the development of perioperative cancer treatments.
Matea Zosso-Pavic, Francesco Pignatti, Anita Wolfer, Qiyu Li, Pierre Demolis

Lancet Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and ongoing initiatives towards better integrated EU scientific advice.
Iordanis Gravanis, Michael Berntgen, Spiros Vamvakas, Pierre Demolis, Paolo Foggi

Front Med (Lausanne)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.
Sarah A Holstein, Nizar Bahlis, P Leif Bergsagel, Manisha Bhutani, Niccolo Bolli, Pierre Demolis

Transplant Cell Ther· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can a Multistakeholder Prioritization Structure Support Regulatory Decision Making? A Review of Pediatric Oncology Strategy Forums Reflecting on Challenges and Opportunities of this Concept.
Dominik Karres, Giovanni Lesa, Franca Ligas, Pia Annunen, Maaike van Dartel, Pierre Demolis

Clin Pharmacol Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.
Andrew D J Pearson, Claudia Rossig, Giovanni Lesa, Scott J Diede, Susan Weiner, Pierre Demolis

Eur J Cancer· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children.
Andrew D J Pearson, Nicole Scobie, Koenraad Norga, Franca Ligas, Davy Chiodin, Pierre Demolis

Eur J Cancer· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.
Kyriaki Tzogani, Jorge Camarero Jiménez, Isabel Garcia, Arantxa Sancho-López, Marc Martin, Pierre Demolis

Oncologist· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for Human Use.
Marta Kollb-Sielecka, Pierre Demolis, Joseph Emmerich, Greg Markey, Tomas Salmonson

Sleep Med· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protocolisation, Use and Development of Anti-Cancer Drugs in the Context of T2A (Case-Mix Based Payment System) Set-Up.
Anne Mathieu-Boué, Pierre Demolis, Jean-François Bergmann,

Therapie· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Maria Nieto, Pierre Demolis, Eliane Béhanzin, Alexandre Moreau, Ian Hudson

Oncologist· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The European Medicines Agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP).
Kyriaki Tzogani, Nithyanandan Nagercoil, Robert James Hemmings, Bekkai Samir, Jean Gardette, Pierre Demolis

Eur J Dermatol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Elias Pean, Pierre Demolis, Alexandre Moreau, Robert James Hemmings, Daniel O'Connor

Oncologist· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative validation of the growth hormone-releasing hormone and arginine test for the diagnosis of adult growth hormone deficiency using a growth hormone assay conforming to recent international recommendations.
Philippe Chanson, Anne Cailleux-Bounacer, Jean-Marc Kuhn, Georges Weryha, Olivier Chabre, Pierre Demolis

J Clin Endocrinol Metab· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metoclopramide treatment in DBA patients: no complete response in a French prospective study.
Thierry M Leblanc, Lydie Da Costa, Isabelle Marie, Pierre Demolis, Gilbert Tchernia

Blood· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protocolisation, use and development of anti-cancer drugs in the context of T2A (case-mix based payment system) set-up.
Anne Mathieu-Boué, Pierre Demolis, Jean-François Bergmann

Therapie· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of the postoperative pericardial effusion after day 15: the problem of the late tamponade.
Philippe Meurin, Hélène Weber, Nathalie Renaud, Fabrice Larrazet, Jean Yves Tabet, Pierre Demolis

Chest· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative pharmacokinetics and pharmacodynamics of intravenous and oral nefopam in healthy volunteers.
Guy Aymard, Dominique Warot, Pierre Démolis, Jean François Giudicelli, Philippe Lechat

Pharmacol Toxicol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Avoidable hospital drug prescription in the elderly. A review of the literature].
Fabien Lesourd, Anne-Marie Mathieu, Joël Ankri, Marie-Laure Pibarot, Olivier Henry, Pierre Demolis

Ann Med Interne (Paris)· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis